Skip to main content
. 2016 Oct 20;2016:7168280. doi: 10.1155/2016/7168280

Table 2.

Indications, findings, and interventions for inpatient versus ASC ERCP, EUS, and the total population.

 ERCP EUS Total
IN ASC ALL p (95% CI) IN ASC ALL p (95% CI) IN ASC ALL p (95% CI)
Indications
Biliary
 Obstructive jaundice 39 (51%) 37 (23%) 76 (32%) 0.0005 10 (46%) 8 (7%) 18 (13%) 0.07 49 (50%) 45 (16%) 94 (25%) <0.0001
 SOD 24 (32%) 40 (25%) 64 (27%) 0.02 3 (14%) 8 (7%) 11 (8%) 0.98 27 (28%) 48 (17%) 75 (20%) 0.02
 Dilated biliary ductal system 31 (41%) 25 (16%) 56 (24%) < 0.0001 4 (18%) 5 (4%) 9 (7%) 0.94 35 (36%) 30 (11%) 65 (17%) 0.003
 Choledocholithiasis 19 (25%) 22 (14%) 41 (17%) 0.046 0 0 0 1.00 19 (19%) 22 (8%) 41 (11%) 0.55
 Elevated LFT 17 (20%) 5 (3%) 22 (9%) 0.0002 3 (14%) 1 (1%) 4 (3%) 1.00 20 (20%) 6 (2%) 26 (7%) 0.004
 Cholangitis 9 (12%) 0 9 (4%) 0.92 0 0 0 1.00 9 (9%) 10 (3%) 9 (2%) 1.00
 Biliary stricture 3 (4%) 8 (5%) 11 (5%) 0.37 1 (5%) 1 (1%) 2 (1%) 0.99 4 (4%) 9 (3%) 13 (4%) 0.62
 Stent extraction 9 (12%) 28 (18%) 37 (16%) 0.12 1 (5%) 0 1 (1%) 0.99 10 (10%) 28 (10%) 38 (10%) 0.03
 Bile leak 10 (13%) 14 (9%) 24 (10%) 0.53 1 (5%) 0 1 (1%) 0.98 11 (11%) 14 (5%) 25 (7%) 0.35
Pancreatic
 Pancreatic mass 8 (11%) 10 (6%) 18 (8%) 0.09 6 (27%) 26 (22%) 32 (23%) 0.19 14 (14%) 36 (13%) 50 (13%) <0.0001
 Pancreatic cyst 0 6 (4%) 6 (3%) 0.96 1 (5%) 38 (33%) 39 (28%) 0.22 1 (1%) 44 (16%) 45 (12%) <0.0001
 Chronic pancreatitis 2 (3%) 16 (10%) 18 (8%) 0.11 1 (5%) 8 (7%) 9 (7%) 0.37 3 (3%) 24 (9%) 27 (7%) 0.48
 Gall stone pancreatitis 11 (15%) 1 (1%) 12 (5%) 0.003 3 (14%) 3 (3%) 6 (3%) 0.02 14 (14%) 4 (1%) 18 (5%) 0.009
 Pancreatic divisum 1 (1%) 10 (6%) 11 (5%) 0.11 0 2 (2%) 2 (1%) 0.99 1 (1%) 14 (5%) 15 (4%) 0.44
Neoplastic
 Any neoplasm 11 (15%) 12 (8%) 23 (10%) 0.10 3 (14%) 29 (25%) 32 (23%) 0.61 21 (21%) 44 (16%) 65 (17%) <0.0001
 Palliation neoplasm 5 (7%) 1 (1%) 6 (3%) 0.06 2 (9%) 0 2 (1%) 1.00 7 (7%) 1 (1%) 8 (2%) 0.50
 Staging of neoplasm 6 (8%) 6 (4%) 12 (5%) 0.68 5 (23%) 46 (39%) 51 (37%) 0.98 11 (11%) 52 (19%) 63 (17%) <0.0001
Generalized
 Chronic abdominal pain 8 (11%) 53 (33%) 61 (26%) 0.0004 0 6 (5%) 6 (3%) 0.99 8 (8%) 59 (21%) 67 (18%) <0.0001
Intervention
ERCP
 Biliary
  EBS 57 (75%) 108 (68%) 165 (70%) <0.0001 NA 1.00 57 (58%) 108 (39%) 165 (44%) <0.0001
  Needle knife 1 (1%) 1 (1%) 2 (1%) 1.00 NA 1.00 1 (1%) 1 (1%) 2 (1%) 1.00
  SEMS 12 (16%) 5 (3%) 17 (8%) 0.06 NA 1.00 12 (12%) 5 (2%) 17 (5%) 0.06
  Plastic stent 23 (30%) 18 (11%) 41 (17%) 0.003 NA 1.00 23 (24%) 18 (7%) 41 (11%) 0.003
  Cytology 11 (15%) 22 (14%) 33 (14%) 0.0002 NA 1.00 11 (1%) 22 (8%) 33 (9%) 0.0002
  Cholangioscopy 4 (5%) 11 (7%) 15 (11%) 0.40 NA 1.00 4 (4%) 11 (4%) 15 (4%) 0.40
  Manometry 2 (3%) 18 (11%) 20 (9%) 0.47 NA 1.00 2 (2%) 18 (7%) 20 (5%) 0.47
 Pancreatic
  EPS 6 (8%) 30 (19%) 36 (15%) 0.03 NA 1.00 6 (6%) 30 (11%) 36 (10%) 0.03
  Minor duct papillotomy 1 (1%) 8 (5%) 9 (4%) 0.92 NA 1.00 1 (1%) 8 (3%) 9 (2%) 0.92
  PD Stent 21 (28%) 44 (28%) 65 (28%) 1.00 NA 1.00 21 (21%) 44 (16%) 65 (17%) 0.60
 Ampullary biopsy 2 (3%) 13 (8%) 15 (6%) 0.13 0 1 (1%) 1 (1%) 1.00 3 (3%) 14 (5%) 17 (5%) 0.81
EUS
 FNA NA 1.00 12 (55%) 77 (66%) 89 (64%) <0.0001 12 (12%) 77 (28%) 89 (24%) <0.0001

ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; IN: inpatients; ASC: ambulatory surgical center patients; ALL: inpatients + ASC patients; GI: gastrointestinal; LFT: liver function tests; SOD: sphincter of Oddi dysfunction; GIST: gastrointestinal stromal tumor; IPMN: intraductal papillary mucinous neoplasm; NE: neuroendocrine; EBS: endoscopic biliary sphincterotomy; EPS: endoscopic pancreatic sphincterotomy; SEMS: self-expanding metal stent; FNA: fine needle aspiration.

Note that p < 0.01 is significant.